Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational research

Fig. 2

Antitumor efficacy of olverembatinib in patients with SDH-deficient GISTs. a Duration of treatment and best response (RECIST v1.1). Each row represents one patient’s duration of treatment with her/his best response. The three left columns show the treatment history, gene mutation, and dose received by each patient. (Im, imatinib; Sun, sunitinib; Das, dasatinib; Reg, regorafenib; Rip, ripretinib; Anlo, anlotinib; Fam, famitinib; TMZ, temozolomide; PD-1, monoclonal antibody targeting PD-1. PD, progressive disease; PR, partial response; SD, stable disease. b Kaplan‒Meier estimates of progression-free survival (PFS) by RECIST v1.1. The median PFS was 25.7 months (range, 12.9 to not reached) for olverembatinib in SDH-deficient patients (indicated by the red solid line) and 2.9 months (range, 1.7–5.2) in non-SDH-deficient patients (indicated by the purple solid line). c Median (range) PFS was 6.0 (2.0–10.0) and 5.5 (1.0–8.0) months for sunitinib and regorafenib, respectively (indicated by the green and blue dotted lines)

Back to article page